← Back
Kymera Therapeutics
KYMR · listed on Nasdaq · worth $10.95 billion
$127.09
−0.33% today
Two insider buys in the last year, $172.5 million in all. None in the last two weeks.
Green dot = an insider bought red = sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
68.3M shares
80% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider bought Kymera Therapeutics stock and ten insiders sold. Seven of the 200 sales are marked on the filing as planned in advance. The biggest seller was Bruce Booth.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
10% owner
Baker Bros. Advisors LP
Bought $158.12M on Dec 11, 2025 — 1,838,621 shares at $86.00, held through a trust or family, 23% of what they now own.
5 of 5 earlier purchases did better than the S&P 500
Planned sales
Form 144 notices filed for Kymera Therapeutics in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
CEO Nello Mainolfi filed to sell 30,000 shares on 1 Oct; sold 30,000 by 1 Oct10b5-1 plan adopted 24 Mar 2026 · Notice on SEC.gov
Executive Brian Adams filed to sell 6,371 shares on 4 Sep; sold 6,371 by 4 SepNotice on SEC.gov
COO Jeremy G. Chadwick filed to sell 10,879 shares on 2 Sep; no sale reported yet10b5-1 plan adopted 10 Dec 2025 · Notice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Kymera Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateBlackRock6.6%Oct 27
Filed by someone who owns 5% or more and does not plan to influence the company. · updateAtlas Venture Fund X2.9%Aug 13
Filed by someone who owns 5% or more and may try to influence how the company is run. · updateBiotechnology Value Fund L P3.3%Jun 26
All reports
Every insider trade and SEC report we hold for Kymera Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 1SoldNello MainolfiOct 1 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.262 @ $116.12$30.4K
Oct 1SoldNello MainolfiOct 1 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.8,230 @ $115.40$949.7K
Oct 1SoldNello MainolfiOct 1 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.7,601 @ $114.43$869.8K
Oct 1SoldNello MainolfiOct 1 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.4,876 @ $113.24$552.2K
Oct 1SoldNello MainolfiOct 1 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.5,506 @ $112.42$619K
212 more with Pro →Analysts, earnings and news
Analysts' price target
$123.76 average
21 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 4 quarters above
Q1 '26−$0.71 a share+$0.15
Q4 '25−$0.98 a share−$0.21
Q3 '25−$0.94 a share−$0.16
Q2 '25−$0.95 a share−$0.15